Minimizing Uncertainty
Max Ostermeier on Favorable Environments: ImplantData’s Eyemate-SC targets glaucoma’s $8.34B therapeutics sector, leveraging FDA Breakthrough Designation for expedited reimbursement and market entry, fostering job creation in digital health. He details funding pathways from pre-seed to exits, aligning with policy incentives for chronic disease management.